Oncotarget

Research Perspectives:

Clinical application of liquid biopsies to detect somatic BRCA1/2 mutations and guide potential therapeutic intervention for patients with metastatic breast cancer

Neelima Vidula _, Leif W. Ellisen and Aditya Bardia

PDF  |  Full Text  |  How to cite  |  Order a Reprint

Oncotarget. 2021; 12:63-65. https://doi.org/10.18632/oncotarget.27863

Metrics: PDF 208 views  |   Full Text 524 views  |   ?  


Abstract

Neelima Vidula1, Leif W. Ellisen1 and Aditya Bardia1

1 Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

Correspondence to:

Neelima Vidula,email: nvidula@mgh.harvard.edu

Keywords: cell-free DNA; BRCA1/2; PARP inhibitor; metastatic breast cancer; plasma based genotyping

Received: November 19, 2020     Accepted: December 22, 2020     Published: January 19, 2021

Copyright: © 2021 Vidula et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

Plasma based genotyping via cell-free DNA may identify actionable mutations for potential therapeutic intervention in patients with advanced malignancies including breast cancer. In this article, we discuss recent studies using cell-free DNA testing to identify and classify somatic BRCA1/2 mutations in metastatic breast cancer, and potential future applications for the treatment of metastatic breast cancer.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 27863